DELRAY BEACH, Fla., Aug. 03, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation (“VeriTeQ” or the “Company”) (OTC Markets:VTEQD), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has retained prominent plastic surgeon Dr. Michael A. Fiorillo as a consultant to the Company.
Dr. Fiorillo is a double board certified plastic and cosmetic surgeon renowned worldwide as an authority in the field. He is a distinguished author with numerous publications on plastic surgery, including peer-reviewed medical articles, books, and textbooks. Highly respected by his patients and the plastic surgery community, Dr. Fiorillo’s expertise has won him the trust of the thousands of patients that have attended his practices in New York and New Jersey since 1998. His expertise and thousands of successful surgeries have brought him the honor of being appointed by Sientra, one of only three FDA cleared breast implant marketers in the U.S., to train other doctors in the United States.
“Q Inside Safety Technology can offer significant benefits to the plastic surgery industry, and I am pleased to assist VeriTeQ with its mission of improving patient safety and ensuring device quality,” stated Dr. Fiorillo.
Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ, stated, “We have a strong relationship with Dr. Fiorillo, an expert in the medical aesthetic industry, which we believe can help us increase awareness of the benefits offered by our Q Inside Safety Technology™ among medical device manufacturers, physicians and patients.”
VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients with access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as “may,” “expect,” “anticipate," “intend," “estimate” or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to continue to raise capital to fund its operations; VeriTeQ’s ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ’s control. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 14, 2015. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact: VeriTeQ Allison Tomek, 561-846-7003 email@example.com